Alzheimer’s Disease and COVID-19 Pathogenic Overlap: Implications for Drug Repurposing
Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · 2024-03 · 51 (2) · 161-172
DOI: 10.1017/cjn.2023.39 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques, online erschienen am 30.03.2023. Verfasst von Mahdieh Golzari-Sorkheh und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology, University of Toronto, Toronto, ON, Canada. Hauptthemen laut MEDLINE: Alzheimer Disease, COVID-19. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 118 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Demenz
Abstract (Originalsprache)
As COVID-19 continues, a safe, cost-effective treatment strategy demands continued inquiry. Chronic neuroinflammatory disorders may appear to be of little relevance in this regard; often indolent and progressive disorders characterized by neuroinflammation (such as Alzheimer’s disease (AD)) are fundamentally dissimilar in etiology and symptomology to COVID-19’s rapid infectivity and pathology. However, the two disorders share extensive pathognomonic features, including at membrane, cytoplasmic, and extracellular levels, culminating in analogous immunogenic destruction of their respective organ parenchyma. We hypothesize that these mechanistic similarities may extent to therapeutic targets, namely that it is conceivable an agent against AD’s immunopathy may have efficacy against COVID-19 and vice versa. It is notable that while extensively investigated, no agent has yet demonstrated significant therapeutic efficacy against AD’s cognitive and memory declines. Yet this very failure has driven the development of numerous agents with strong mechanistic potential and clinical characteristics. Having already approved for clinical trials, these agents may be an expedient starting point in the urgent search for an effective COVID-19 therapy. Herein, we review the overlapping Alzheimer’s/ COVID-19 targets and theorize several initial platforms.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Immunology, University of Toronto, Toronto, ON, Canada.
- Krembil Research Institute, University Health Network, Toronto, ON, Canada.
- Department of Pharmacology & Toxicology, University of Toronto, Toronto, ON, Canada.
- Department of Pharmaceutical Sciences, University of Toronto, Toronto, ON, Canada.
- Department of Chemistry, University of Toronto, Toronto, ON, Canada.
ORCID-Profile: Donald F Weaver
Zitieren
APA
Golzari-Sorkheh, M., Liyanage, I., Reed, M. A., & Weaver, D. F. (2024). Alzheimer’s Disease and COVID-19 Pathogenic Overlap: Implications for Drug Repurposing. Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques, 51(2), 161-172. https://doi.org/10.1017/cjn.2023.39
Vancouver
Golzari-Sorkheh M, Liyanage I, Reed MA, Weaver DF. Alzheimer’s Disease and COVID-19 Pathogenic Overlap: Implications for Drug Repurposing. Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques. 2024;51(2):161-172. doi:10.1017/cjn.2023.39
BibTeX
@article{GolzariSorkheh2024,
author = {Golzari-Sorkheh, Mahdieh and Liyanage, Imindu and Reed, Mark A and Weaver, Donald F},
title = {Alzheimer’s Disease and COVID-19 Pathogenic Overlap: Implications for Drug Repurposing},
journal = {Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques},
year = {2024},
volume = {51},
number = {2},
pages = {161--172},
doi = {10.1017/cjn.2023.39}
}
EUVIMED